MiMedx Launches First-Ever Human Placental Derived Surgical Recovery Product

Biologics company, MiMedx (Nasdaq: MDXG) has launched AXIOFILL™, a cost-effective surgical recovery product ideal for use in large, complex wounds and those of irregular geometries.

AXIOFILL provides a distinct advantage over other particulate products and provides impressive clinical utility for physicians treating complex surgical wounds.

 Highlights

  • Mimedx’s product is the first and only human placental-derived particulate product available for surgical recovery procedures
  • It offers a competitive advantage over other xenograft, or animal-based, particulate products;
  • The product is a human collagen scaffold that supports key regenerative processes, including cellular infiltration and neovascularization needed for the generation of functional tissue.

Dr. Susan Hagen, General Surgeon, Boulder, CO. said AXIOFILL offers a safe, convenient and powerful tool that can be used in a wide variety of surgical applications.

Share This Article

 

About the Author

MiMedx Launches First-Ever Human Placental Derived Surgical Recovery Product

Editor Prism MarketView